Participant flow

An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome · Source last updated 2014-04-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   mifepristone at doses from 300 mg/day up to 1200 mg/day daily

   id

   FG000

   title

   Open-label

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         30

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         21

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         9

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

Only subjects who had completed C1073-400 (NCT00569582) were enrolled. All subjects received active drug (no placebo).

recruitment Details

Subjects completing 24 weeks of mifepristone treatment under Corcept protocol C1073-400 (NCT00569582) were eligible to continue treatment in C1073-415 at the dose being administered at the end of treatment in C1073-400 (NCT00569582).

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice